Collaborative Arrangements and Licensing Agreements (Tables)

12 Months Ended

Dec. 31, 2023

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with Biogen (in thousands, except percentage amounts):

	Year Ended December 31,
	2023			2022			2021
Revenue from our relationship with Biogen	$	350,146		$	366,696		$	428,784
Percentage of total revenue		44	%		62	%		53	%

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):

	Year Ended December 31,
	2023			2022			2021
Revenue from our relationship with AstraZeneca	$	202,236		$	79,160		$	254,591
Percentage of total revenue		26	%		13	%		31	%

GSK [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with GSK (in thousands, except percentage amounts):

	Year Ended December 31,
	2023			2022			2021
Revenue from our relationship with GSK	$	15,000		$	—		$	—
Percentage of total revenue		2	%		0	%		0	%

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with Novartis (in thousands, except percentage amounts):

	Year Ended December 31,
	2023			2022		2021
Revenue from our relationship with Novartis	$	30,194		$	237	$	25,526
Percentage of total revenue		4	%	Less than 1%			3	%

Otsuka [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the year ended December 31, 2023, we earned the following revenue from our relationship with Otsuka (in thousands, except percentage amount):

	Year Ended December 31,
	2023
Revenue from our relationship with Otsuka	$	56,480
Percentage of total revenue		7	%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with Roche (in thousands, except percentage amounts):

	Year Ended December 31,
	2023			2022			2021
Revenue from our relationship with Roche	$	48,838		$	67,202		$	17,241
Percentage of total revenue		6	%		11	%		2	%

Sobi [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our distribution agreement with Sobi for TEGSEDI in North America (in thousands, except percentage amounts):

	Year Ended December 31,
	2023		2022			2021
TEGSEDI revenue from our distribution agreement with Sobi in North America	$	2,646	$	4,004		$	7,443
Percentage of total revenue	Less than 1%			1	%		1	%

Alnylam [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the years ended December 31, 2023, 2022 and 2021, we earned the following revenue from our relationship with Alnylam (in thousands, except percentage amounts):

	Year Ended December 31,
	2023			2022			2021
Revenue from our relationship with Alnylam	$	28,426		$	21,389		$	—
Percentage of total revenue		4	%		4	%		0	%